Novartis Gene Therapies Global Managed Access Program
Novartis Gene Therapies recommits to Global Managed Access Program for 2021 so that children around the world can benefit from SMA treatment who otherwise would not have access to Zolgensma.
Sandoz spin-off
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.
Latest news
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Novartis in Society Integrated Report 2021
In 2021, we continued to reimagine medicine and deliver on our purpose to improve and extend people’s lives. See more in our Integrated Report.
Environmental, Social and Governance
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices.
Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Live Magazine
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.
